Thromboembolism and anticoagulation after Fontan surgery

Area of Science:

• Cardiology
• Pediatric Cardiology
• Hematology

Background:

• Fontan surgery is a palliative procedure for complex congenital heart disease.
• Patients undergoing Fontan operation have a significantly elevated risk of thromboembolic events.
• Thromboembolism in this population can lead to severe morbidity and mortality.

Purpose of the Study:

• To address clinical questions regarding thromboembolism and thromboprophylaxis in post-Fontan patients.
• To review current literature and provide practical, evidence-based solutions for clinicians.
• To clarify the optimal strategy for preventing blood clots in this high-risk group.

Main Methods:

• A comprehensive review of existing medical literature.
• Question-and-answer format to address common clinical queries.
• Synthesis of evidence to guide clinical decision-making.

Main Results:

• Strong evidence supports the need for thromboprophylaxis in Fontan patients.
• Current literature suggests antiplatelet agents may be comparable to oral anticoagulants.
• No definitive consensus exists on the superior thromboprophylactic agent.

Conclusions:

• Fontan survivors require vigilant thromboembolism risk management.
• Further large-scale randomized controlled trials are essential to compare antiplatelet therapy versus oral anticoagulation.
• A clear verdict on the best thromboprophylaxis strategy is needed to optimize patient outcomes.